Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
about
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-AnalysisResearch Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKIUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsDownregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case reportA new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC PatientsSignificance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesImpact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.An active treatment of lung adenocarcinoma cancer with brain metastases: icotinibEnhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80.Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancerEGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report.Differences in clinical presentation of non-small cell lung cancer in never-smokers versus smokersTargeted therapies in brain metastases.First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?Growth factor signaling in metastasis: current understanding and future opportunities.EGFR mutation status in brain metastases of non-small cell lung carcinoma.Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.Brain metastasis: new opportunities to tackle therapeutic resistance.The management of brain metastases in non-small cell lung cancer.Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.The future of targeted therapies for brain metastases.Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status.Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Updates in the management of brain metastases.Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).Inhibitors of the Epidermal Growth Factor Receptor (EGFR) May Provide Effective Treatment for Lung Adenocarcinoma.Efficacy assessment of pemetrexed treatment of an NSCLC case with brain metastasis.Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.
P2860
Q26752378-944EA890-A153-4827-A24A-483BFE684D0DQ26798043-2AE40F6D-699B-4AD7-8872-87FCD73CA6B0Q28075291-1FB9F940-191D-4BDB-AFE0-EDCB384F9755Q33597567-BCF622DB-7452-478A-8955-FE8666BA1088Q34406424-8C6FB18D-CC96-4C67-AFD6-F16D69A2B173Q34497467-F1D2A909-8DC5-4FBD-93B2-4EB2406B92DEQ34762545-5F6ECB9F-A3AB-48F0-991E-3E9E39369237Q34886787-D16833AF-EEA1-46F2-B4F8-7C16CB6F8EEEQ35587238-1EB3EDBC-624B-429F-ACF6-48C4A13E1E9EQ35743177-8AAB3F9C-383A-4F9C-A92B-8ADC5A2FD2A9Q36212979-AAFE4139-F418-4B0F-BEDC-1BA0892970DBQ36372611-208389A5-DF03-4608-87A3-494D076A3E28Q36422709-D8AF34D9-7DC1-4EE4-BC87-4EEA5D4C1666Q36600202-FD3CEDB6-FF0F-4BE8-8BAA-6924390D0066Q36984851-1F55F5DF-02DF-41FF-A690-F0F8F588A06AQ37345446-54D7CC6D-7526-4963-AB38-03068B8520BAQ37457385-E6F84F67-78F1-4822-AA29-51BC92AD1E3FQ37491460-7C692100-A31A-4208-9351-DB17A7C9A38CQ37544367-680B51D0-BB4C-4B07-9B05-336D77C567A1Q37639588-9683CAAA-747A-452D-BECC-87B745EEACE7Q37646729-49DADB29-756D-4E71-9D0D-AEA264634CB6Q37738403-CEDA4EA0-1D55-47C5-974A-CF978A14003DQ38019410-E49FB21B-1A34-4E30-BB74-FC891BEDACD0Q38053963-8BF7F1B3-4C75-43F2-A6A3-66A8832EA715Q38054713-B8FBEB92-EF2E-48AA-B46E-7301F3DCE784Q38222247-554ADF37-F8F5-49D4-9853-E613370A6F3CQ38259586-6EC87BB5-22A9-4A16-A35A-50A1E0A93C08Q38292832-C41F7E8F-7816-4523-883D-4E50B9337083Q38564085-A155B66F-E94E-41C0-9E46-E0B9A49E2961Q38734802-32B73872-656E-43E3-876A-29D98C40B3FDQ38763104-BC5BB4D8-5918-448F-9EAE-98CAB2F9E980Q38763111-D873A072-2458-4848-9172-8369B7DA0BB8Q38770028-AE81F765-59A2-4492-93E9-1DBE14AC195DQ38887451-443ECE07-D0D9-4DE9-8E6F-0333031E8FC0Q38913258-6FA0AFE9-87CC-4ABD-A78C-8A2A43C6EAEBQ38991958-6C20F743-D670-4848-851A-DD162DF958EFQ39229266-929427E6-E62E-4A51-B76B-C6E834B1092CQ41108508-9FE172FB-1117-4796-9128-22ED82C77FBEQ41115642-469E7018-33B6-44D7-917A-82349A7A612EQ41189462-1215232E-30E9-4AD7-B2E3-9E64A9A61D17
P2860
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Epidermal growth factor recept ...... ancer metastatic to the brain.
@en
Epidermal growth factor recept ...... ancer metastatic to the brain.
@nl
type
label
Epidermal growth factor recept ...... ancer metastatic to the brain.
@en
Epidermal growth factor recept ...... ancer metastatic to the brain.
@nl
prefLabel
Epidermal growth factor recept ...... ancer metastatic to the brain.
@en
Epidermal growth factor recept ...... ancer metastatic to the brain.
@nl
P1476
Epidermal growth factor recept ...... ancer metastatic to the brain.
@en
P2093
James Spicer
Mariam Jamal-Hanjani
P304
P356
10.1158/1078-0432.CCR-11-2529
P407
P577
2011-12-13T00:00:00Z